Bayer (FRA:BAYN) received a €110.00 ($123.60) target price from equities researchers at UBS Group in a report released on Tuesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the healthcare company’s stock. UBS Group’s price target would suggest a potential upside of 70.54% from the company’s current price.
BAYN has been the topic of several other research reports. Deutsche Bank set a €87.00 ($97.75) price target on shares of Bayer and gave the stock a “buy” rating in a research note on Friday. HSBC set a €85.00 ($95.51) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Thursday, June 25th. Warburg Research set a €81.00 ($91.01) price objective on shares of Bayer and gave the stock a “neutral” rating in a report on Thursday, July 2nd. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a report on Tuesday, July 7th. Finally, Kepler Capital Markets set a €73.00 ($82.02) price objective on shares of Bayer and gave the stock a “neutral” rating in a report on Thursday, June 25th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of €84.41 ($94.84).
Shares of BAYN opened at €64.50 ($72.47) on Tuesday. The company’s fifty day moving average is €65.18 and its 200-day moving average is €65.01. Bayer has a 12 month low of €91.58 ($102.90) and a 12 month high of €123.82 ($139.12).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: Why do analysts give a neutral rating?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.